Home » Newsletters » BioWorld Science

BioWorld Science

June 21, 1996

View Archived Issues

RPR describes RPR-107880 synthesis

5alpha-reductase type 1 inhibitors from Merck & Co.

KCB-1 skin ulcer clinical trials completed

Positive phase III results for new Solarase formulation

Collagen Corporation and Biomatrix enter marketing agreement

FDA approves abbreviated treatment regimen for Vantin

Antifungal sordarin derivatives reported by Glaxo Wellcome

Positive analysis results for Amphotec

AmBisome line extension receives Danish approval

Alpha-glucosidase inhibitors from Seikagaku Kogyo

HIV protease inhibitors from Warner-Lambert

Y-ART-3: Promising HIV treatment candidate

Albenza receives U.S. marketing approval

Toyama's T-614 enters phase I in U.K.

Cyclolignan derivatives disclosed

Antibody production-enhancing peptides described

Anergen issued European patent on AnergiX compounds

RPR granted rights to Gliadel

Bristol-Myers Squibb isolates and synthesizes hayumicin antitumor antibiotics

Pierre Fabre reveals cancer treatment agents

DX-8951f enters phase I

Camptosar approved in U.S.

Antitumor baccatin derivatives from Tanabe Seiyaku

Positive preclinical results for Onconase reported

LHRH antagonists disclosed by Takeda

Multikine covered under Japanese patent

Potential cancer/nephritis derivatives reported

Development of DS-4152 for Kaposi's sarcoma in AIDS patients terminated

Universidad de Salamanca reveals LL-15

Breast/prostate cancer treatment agents reported

Encouraging preclinical results for G-3139

Onyx and Lilly expand BRCA1 research agreement

TH-9402 covered under U.S. patent

Lu-Tex deemed safe and effective in phase I trial

Calcium receptor modulators from NPS Pharm.

Astra acquires worldwide rights to ALX1-11

Orquest's Healos enters clinical trials

Research results of SomatoKine as catabolism treatment

Redux launched in U.S.

Ceredase approved in Japan

AS-300 and N-CBM-TAMO: Potential agents for treating drug addiction

LIFE-Lung receives FDA approval

Marketing alliance formed by Abbott and Berlex

Pierre Fabre describes 5-HT1 receptor ligands

FDA approves Organon's Remeron

Drug development agreement reached by Megabios and Pfizer

Megabios issued worldwide license to lipid-DNA complexes

RPR Gencell and IntraImmune Therapies enter drug development agreement

Cheung Laboratories and MIT reach marketing agreement

Zeneca to utilize Incyte database and technologies

Competitive Technologies and Mount Sinai School of Medicine sign agreement

Celltech sells Celltech Biologics

BioKePharm and Gruppo Marcucci to merge

Taro's anticonvulsant drug undergoes development

COMT inhibitor disclosed by Roche

Discovery Therapeutic's N-0923 trial results to be presented

Peptides resembling h-MBP claimed

Agents for multiple sclerosis disclosed

Anergen's MS-AnergiX enters phase I for MS

Cholinergic agonists claimed by Lilly

Alzheimer's beta-protein inhibition method described

5-HT1A agonist for cognition disorders disclosed

Conflicting studies on besipirdine

Approval of Daiichi's Translon imminent

Hoechst synthesizes NOS inhibitors

Schering AG claims AMPA antagonists for neurodegenerative disorders

Asahi Brewery discloses antioxidants

Intranasal NPY: Potential allergic rhinitis agent

FDA approval of novel Claritin formulation sought

Results on cough research disclosed

Thiophenolic compounds revealed by Searle

Glaxo Wellcome synthesizes protein-binding agents

Chymase/NO production inhibitors synthesized by Wakamoto

Ono reveals antioxidant TxA2 synthase/5-lipoxygenase inhibitors

B2 antagonists from Servier

Astra's Pulmicort approaches FDA approval

Thymosin beta4 as cystic fibrosis treatment

Endothelin antagonist claimed by Roche

Roussel Uclaf discloses endothelin antagonists

Generic version of indapamide approved in U.S.

Pierre Fabre reveals cardiac cytoprotective agents

TFPI as tissue injury inhibitor

L-arginine is effective in heart failure patients

Vesnarinone treatment recommendations

ST-899 and ST-776 claimed by Sigma-Tau

Roberts' ProAmatine approaches FDA approval

Modified factor VII described for coagulation-related disorders

Mitsubishi Chem.'s Novastan receives Japanese approval for new indication

E. Merck reports fibrinogen (gpIIb/IIIa) antagonists

LM-AS-013 development for peripheral vascular disorders terminated

FDA approval of new indication for Genentech's Activase

Alpha1-adrenoceptor antagonists described

NS-21 licensing options awarded

GelTex's RenaGel enters phase III

Oxis' BXT-51072 will enter phase I

Efficacy and safety of fish oil preparation for Crohn's disease

Genelabs Technologies describes hepatitis E virus

Innovir and The Scripps Research Institute research antihepatitis B drug

Amgen and Yamanouchi to collaborate on Infergen

Anakinra claimed for pancreatitis

Lilly discloses insulin analogues

Teikoku Hormone reveals novel octadecapeptide

Lilly's Humalog reaches first market

Caverject cleared for marketing in Canada

C31G research results reported

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...